{"id":374417,"date":"2026-04-04T08:50:12","date_gmt":"2026-04-04T08:50:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/il\/374417\/"},"modified":"2026-04-04T08:50:12","modified_gmt":"2026-04-04T08:50:12","slug":"psychiatry-and-ai-a-new-era-of-treatment","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/il\/374417\/","title":{"rendered":"Psychiatry and AI: A New Era of Treatment"},"content":{"rendered":"

\"Schizophrenia<\/p>\n

A scan showing areas of brain growth and loss of tissue for a patient with childhood-onset schizophrenia. <\/p>\n

AFP <\/p>\n

Psychiatrists and neuroscientists at a Swiss hospital are combining artificial intelligence (AI) with personalised brain stimulation to move beyond trial-and-error treatment. The goal is to identify which therapy works best for which patient and to deliver it faster.\n<\/p>\n

Listen to the article <\/p>\n

Listening the article <\/p>\n

Toggle language selector <\/p>\n

English (US) <\/p>\n

English (British) <\/p>\n

Generated with artificial intelligence. <\/p>\n

This content was published on <\/p>\n

April 4, 2026 – 09:00\n<\/p>\n

Today, psychiatric treatments for illnesses such as depression can\u00a0take weeks to show effects, for others such as schizophrenia, medicine fails to address all the symptoms. Doctors frequently need to try different medications and doses before finding the right one. More time to find the right treatment means potential side effects from the wrong treatments and more suffering for the patient.\u00a0<\/p>\n

Researchers at HUG (Geneva\u2019s university hospitals) and the University of Geneva (UNIGE) are combining AI technology and brain imaging to tailor treatment to each patient\u2019s brain.\u00a0<\/p>\n

Rather than a lengthy trial-and-error phase, patients could, in the future, undergo a brain scan. Their clinical history and biological data would be analysed using artificial intelligence, helping doctors identify the treatment most likely to work \u2013 whether medication, psychotherapy or brain stimulation. This could be a revolution for how mental health is treated and diagnosed.\u00a0<\/p>\n

\n More<\/p>\n

\"A<\/p>\n

More <\/p>\n

Is psychedelic therapy about to go mainstream? <\/p>\n

\n

This content was published on <\/p>\n

Jul 8, 2024 <\/p>\n

At the Geneva University Hospital, patients can benefit from the only psychedelic-assisted therapy offering in Switzerland. Are such treatments set to spread? <\/p>\n

<\/p>\n

Read more: Is psychedelic therapy about to go mainstream?
\n <\/a><\/p>\n

From understanding the brain to personalising treatment<\/p>\n

For years, neuroscientists have observed how the brain works to identify the different areas involved in mental health disorders. \u201cWe worked on imaging to better understand what happens in the brain,\u201d says Stefan Kaiser, professor of psychiatry at UNIGE and Head of Psychiatry at HUG. \u201cNow we want to use this neuroscientific knowledge to improve care.\u201d<\/p>\n

Matthias Kirschner, a psychiatrist and researcher at HUG, describes the broader ambition as improving \u201cthe crosstalk between research and clinic\u201d. At Campus Biotech, where he receives patients, a new AI hub brings together clinical psychiatry, neuroscience and data science under one roof. The goal of this centre, which opened in December, is not only to test new therapies but to refine them continuously through close interaction between researchers and clinicians.<\/p>\n

Elena Beanato coordinates the collaboration between these specialists, helping facilitate communication with the roughly 50 professionals working within the new structure. \u201cFor years, Campus Biotech has been a centre for neuroscientific research,\u201d she explains. \u201cThe consultation for brain and mental health has joined this environment, creating a setting that now benefits both patients and researchers.\u201d<\/p>\n

Artificial intelligence is expected to play an important role in this model. In December, the centre integrated with Campus Biotech\u2019s AI hub.\u00a0\u201cIn the future, data collected through clinical consultations, brain imaging and research protocols could be analysed to identify patterns that help predict how individual patients respond to treatment,\u201d explains Kirschner. The aim is to move beyond broad diagnostic categories and towards more precise therapeutic choices.<\/p>\n

\n More<\/p>\n

\"woman<\/p>\n

More <\/p>\n

AI and medicine\n <\/p>\n

How AI is used in diagnostics <\/p>\n

\n

This content was published on <\/p>\n

Jan 30, 2026 <\/p>\n

Medical experts now use artificial intelligence to help them diagnose and monitor diseases. But does this mean AI will replace doctors? <\/p>\n

<\/p>\n

Read more: How AI is used in diagnostics
\n <\/a><\/p>\n

Personalised neuromodulation<\/p>\n

One of the most promising tools of precision psychiatry is neuromodulation, through transcranial magnetic stimulation (TMS). Kirschner describes this as a technique that uses magnetic stimulation to influence brain activity. <\/p>\n

TMS is widely used in many countries to treat depression. Although it is available as a clinical treatment in Switzerland, neuromodulation is not covered by basic health insurance so its costs have to be covered privately.<\/p>\n

Patients coming to the hub can access this new therapy as part of a research protocol for the treatment of loss of motivation in patients suffering from schizophrenia. Thirty of them have already taken part in the trial, out of the objective of 70 participants. A larger trial will start in 2027.<\/p>\n

\u201cIf our trials yield conclusive results, an application for regulatory approval could be considered by 2030,\u201d says Indrit B\u00e8gue, who leads this research. Transcranial magnetic stimulation is non-invasive. \u201cMagnetic fields are applied to specific brain regions, stimulating circuits of nerve cells and triggering a therapeutic response.\u201d<\/p>\n

In Geneva, the innovation lies not only in the technique itself but in how it is used.<\/p>\n

Traditionally, neuromodulation targets the same spot brain region in all patients\u2019 brains. The Geneva team is moving away from this one-size-fits-all model.<\/p>\n

\u201cBrains come in all shapes and sizes. If we target the same coordinates in everyone, we will get varying results or no result in some patients,\u201d B\u00e8gue explains.<\/p>\n

Instead, researchers map circuits at the individual level. \u201cWe conduct MRIs on each patient to map their own brain circuit, which serves as brain stimulation targetdetermine their ideal target,\u201d she says. \u201cThe stimulation parameters are then adapted accordingly.\u201d<\/p>\n

\"A<\/p>\n

A researcher observes a woman undergoing transcranial magnetic stimulation (TMS) while under hypnosis. <\/p>\n

Keystone <\/p>\n

Targeting apathy in schizophrenia<\/p>\n

The main focus of this trial is schizophrenia, particularly its negative symptoms: apathy and loss of motivation.<\/p>\n

While hallucinations and delusions can often be reduced with medication, pharmacological treatments \u201cshow very little effect on apathy\u201d, Kaiser explains.<\/p>\n

B\u00e8gue\u2019s team identified a link between the cerebellum and the reward system in schizophrenia. The cerebellum \u201cparticipates like a conductor in reward mechanisms\u201d, according to B\u00e8gue. By stimulating this circuit intensively over five days, researchers aim to improve motivational deficits.<\/p>\n

The objective is to create what she describes as a \u201creset of circuits\u201d, potentially allowing longer-term improvement.<\/p>\n

B\u00e8gue cannot yet comment on the results of this ongoing study. \u201cWhat is encouraging is that this approach seems, so far, to be well tolerated by patients,\u201d she notes.<\/p>\n

With minimal risk of side effects, personalised neuromodulation could, in the long term, complement or reduce reliance on certain psychiatric medications. Researchers believe the approach could eventually extend to other disorders such as certain types of depression.<\/p>\n

The AI dimension: predicting response<\/p>\n

If personalised neuromodulation changes how psychiatrists intervene, artificial intelligence could transform how they make decisions.<\/p>\n

Today, psychiatric care often involves sequential testing of treatments. \u201cIt\u2019s still a bit trial-and-error,\u201d says Kaiser.<\/p>\n

At Campus Biotech\u2019s new AI hub, the ambition is to develop tools that can analyse clinical and imaging data to better characterise patient profiles. The longer-term goal is to identify in advance which kind of therapy is most likely to work for which individual.<\/p>\n

\u201cNot everyone responds to psychotherapy, and not everyone responds to medication or neuromodulation,\u201d says B\u00e8gue.<\/p>\n

She envisions doctors combining patient history, behavioural data and brain scans to recommend the most appropriate treatment from the outset \u2013 whether stimulation, psychotherapy, medication, or a combination.<\/p>\n

A laboratory for precision psychiatry<\/p>\n

\u201cThere are so many subsets of mental diseases. Depression, for example, is a word that covers a lot of different realities,\u201d says Kaiser.<\/p>\n

Precision psychiatry means recognising that heterogeneity and targeting treatment accordingly.<\/p>\n

For patients, that could mean fewer months lost to ineffective therapies, and a healthcare system that adapts to the individual brain, rather than forcing them to follow standardised treatment pathways.<\/p>\n

Edited by Virginie Mangin\/ts<\/p>\n

More <\/p>\n

Would you want to know if you were at risk of a disease? Why or why not? <\/p>\n

\n

How early would you like to know if you were prone to a disease, and have you ever experienced issues with a diagnosis? Tell us about your story.\n <\/p>\n

<\/p>\n

View the discussion
\n <\/a><\/p>\n

Articles in this story <\/p>\n","protected":false},"excerpt":{"rendered":"A scan showing areas of brain growth and loss of tissue for a patient with childhood-onset schizophrenia. AFP…\n","protected":false},"author":2,"featured_media":374418,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10],"tags":[127,179684,70799,163,122753,169185,85,46,179685,3073],"class_list":{"0":"post-374417","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-article","9":"tag-beat-ai-and-medicine","10":"tag-beat-healthcare-innovation","11":"tag-health","12":"tag-health-treatment","13":"tag-hospital-and-clinic","14":"tag-il","15":"tag-israel","16":"tag-production-type-original","17":"tag-therapy"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/374417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/comments?post=374417"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/posts\/374417\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media\/374418"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/media?parent=374417"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/categories?post=374417"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/il\/wp-json\/wp\/v2\/tags?post=374417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}